Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
The Effect of Diabetes Mellitus Type2 on Mobilization and Autologous Hematopoietic Stem Cell Transplantation Outcomes Publisher



M Nikoonezhad MARYAM ; S Parkhideh SAHAR ; E Zamani ERFAN ; M Gholamian MAHDI ; S Parkhideh SAYEH ; A Hajifathali ABBAS
Authors

Source: Indian Journal of Hematology and Blood Transfusion Published:2025


Abstract

Background: The success of hematopoietic stem cell transplantation (HSCT) relies significantly on the effective mobilization and collection of hematopoietic stem cells. However, various factors can lead to failure in hematopoietic stem cell mobilization in some patients, including age, type of malignancy, chemotherapy regimens (such as fludarabine, Melphalan, and Lenalidomide), radiotherapy, bone marrow cellularity, and comorbidities. This study investigates the impact of Diabetes Mellitus type 2 on hematopoietic stem cell mobilization outcomes in patients undergoing autologous transplantation. Materials and Methods: We conducted a retrospective analysis of 43 patients, comparing mobilization efficiency, engraftment times, and blood product transfusion requirements between diabetic and non-diabetic cohorts. Mobilization was achieved using granulocyte colony-stimulating factor (G-CSF), with the specific dosing regimen and timing of apheresis detailed in the methods section. Results: Our findings indicate that diabetic patients exhibited significantly lower CD34 + cell counts and required more engraftment time than their non-diabetic counterparts (P < 0.05). Additionally, diabetic patients had higher rates of blood product transfusions post-transplantation. Conclusion: Our findings have shed light on the impact of Diabetes Mellitus type 2 on Hematopoietic Stem Cells mobilization and autologous transplantation, providing crucial insights for the hematopoietic stem cell transplantation field. It is crucial to recognize that diabetes can significantly affect the outcomes of hematopoietic stem cell transplantation. Factors such as poor stem cell mobilization, prolonged engraftment times, and increased need for blood product transfusions underscore the importance of considering diabetes in HSCT candidates. © 2025 Elsevier B.V., All rights reserved.
Related Docs
View other Related Docs
1. Impact of Preexisting Diabetes Mellitus on Transplantation Outcomes in Hematopoietic Stem Cell Transplantation, Endocrine Research (2015)
2. The Altered Expression of Homing Factors in Cd34+ Hematopoietic Stem Cells Following G-Csf Injection and Its Effects on Transplantation Quality in All Patients, Cell Biology International (2022)
3. Efficacy of Mesenchymal Stem Cell Therapy on Glucose Levels in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis, Journal of Diabetes Investigation (2021)
Experts (# of related papers)
View all Related Experts
Bagher Larijani (5)
Babak Arjmand (4)
Other Related Docs
4. Assessment of Immune-Alternations and Their Correlations With Therapeutic Outcomes of Transplantation of Autologous Mesenchymal and Allogenic Fetal Stem Cells in Patients With Type 1 Diabetes: A Study Protocol, Journal of Diabetes and Metabolic Disorders (2021)
5. The Impact of Delayed Versus Early Administration of Granulocyte Colony-Stimulating Factor Following Autologous Hematopoietic Stem Cell Transplantation on Transplantation Outcome, Frontiers in Oncology (2024)
6. Clinical Outcomes of Fetal Stem Cell Transplantation in Type 1 Diabetes Are Related to Alternations to Different Lymphocyte Populations, Medical Journal of the Islamic Republic of Iran (2022)
7. Investigating the Safety and Efficacy of Hematopoietic and Mesenchymal Stem Cell Transplantation for Treatment of T1dm: A Systematic Review and Meta-Analysis, Systematic Reviews (2022)
8. Administration of Autologous Mesenchymal Stem Cell Transplantation for Treatment of Type 1 Diabetes Mellitus, Iranian Journal of Public Health (2015)
9. Mesenchymal Stem Cell Transplantation in Newly Diagnosed Type-1 Diabetes Patients: A Phase I/Ii Randomized Placebo-Controlled Clinical Trial, Stem Cell Research and Therapy (2022)
10. Optimizing Peripheral Blood Stem Cells Transplantation Outcome Through Amend Relapse and Graft Failure: A Review of Current Literature, Experimental Hematology and Oncology (2017)
11. The Effects of Lower Cd34 Yields After Lowe Dose G-Csf Induction on Long-Term Autologous Stem Cell Transplantation Outcome: A Single Center Study, Transfusion and Apheresis Science (2018)
12. Evaluation of Engraftment and Adverse Effects of Granulocyte Colony Stimulating Factor Versus Peg Granulocyte Colony Stimulating Factor in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation, Iranian Journal of Pharmaceutical Sciences (2021)
13. Stem Cell Therapy for Patients With Diabetes: A Systematic Review and Meta-Analysis of Metabolomics-Based Risks and Benefits, Stem Cell Investigation (2018)
14. Investigating the Route of Administration and Efficacy of Adipose Tissue-Derived Mesenchymal Stem Cells and Conditioned Medium in Type 1 Diabetic Mice, Inflammopharmacology (2020)
15. The Complementary Role of Supportive and Palliative Care in Enhancing Bone Marrow Transplant Outcomes, Journal of Pain and Palliative Care Pharmacotherapy (2025)
16. Treatment of Diabetic Mice by Microfluidic System-Assisted Transplantation of Stem Cells-Derived Insulin-Producing Cells Transduced With Mirna, Life Sciences (2021)
17. Dual in Vivo T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation With Post-Transplant Cyclophosphamide and Anti-Thymocyte Globulin As a Third Salvage Transplant for Leukocyte Adhesion Deficiency With Graft Failure: A Case Report, Frontiers in Immunology (2024)
18. Challenges in Managing Graft-Versus-Host Disease in Developing Countries: A Perspective, Bone Marrow Transplantation (2019)
19. Outcome of Peripheral Blood Allogeneic Hematopoietic Stem Cell Transplantation As a Treatment Option in Patients With Severe Aplastic Anemia Between 40 and 50 Years, Hematology/ Oncology and Stem Cell Therapy (2022)
20. Immunomodulatory and Protective Effects of Adipose Tissue-Derived Mesenchymal Stem Cells in an Allograft Islet Composite Transplantation for Experimental Autoimmune Type 1 Diabetes, Immunology Letters (2017)